Biopharmaceuticals in European hospitals

Project managerSteinar Strøm
ClientNorges forskningsråd
Client project no.
ParticipantsUgo Colombino
Marilena Locatelli
Period2010 - 2012 (ended)

Project description

In this project we analyze how prices and funding schemes affect the medical doctors use of different types of biopharmaceuticals in the treatment of arthritis. There are three drugs available in the European markets: Enbrel, Remicade and Humira. Data covers the last 10 years and 10 European countries, including the Nordic countries.


Scientific Journal

Dalen, Dag Morten, Marilena Locatelli, Enrico Sorisio, Steinar StrømDoes the Identity of the Third-Party Payer Matter for Prescribing Doctors?2014Applied Economics and Finance vol 1(1), 39-54[PDF]
Brekke, K.R., D.M. Dalen og S. StrømShould pharmaceutical costs be curbed?2012Nordic Economic Policy Review 2, 1-27[PDF]

Other publications

Dalen, Dag Morten, Enrico Sorisio and Steinar StrømChoosing among Competing Blockbusters: Does the Identity of the Third-Party Payer Matter for Prescribing Doctors?2010CESifo Working paper no. 3227[PDF]
Dalen, Dag Morten, Marilena Locatelli and Steinar StrømLongitudinal Analysis of Generic Substitution2010CESifo Working paper no. 3176[PDF]